ConductScience.org, home

Paper39796647

New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.

Liu L and 2 others. Cancers (Basel), 2024. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective. Papers, record 39796647. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796647

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
4.18, provisional
iCite
Revised in PubMed
2025-01-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu LLiuhttps://orcid.org/0009-0002-5329-4666
2Graff SLStephanie L
3Wang YYihong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References58

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135842959Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.Comput Biol Chem2022https://conductscience.org/library/papers/35842959PubMed
227237051Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.Mol Cell2016https://conductscience.org/library/papers/27237051PubMed
319800812Variation in breast cancer subtypes with age and race/ethnicity.Crit Rev Oncol Hematol2010https://conductscience.org/library/papers/19800812PubMed
430911337HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.Ther Adv Med Oncol2019https://conductscience.org/library/papers/30911337PubMed
526627007Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.Cancer Res2015https://conductscience.org/library/papers/26627007PubMed
626673665Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.Cell Death Dis2015https://conductscience.org/library/papers/26673665PubMed
731752925Distinct functions of AKT isoforms in breast cancer: a comprehensive review.Cell Commun Signal2019https://conductscience.org/library/papers/31752925PubMed
826759240Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.Cancer Res2016https://conductscience.org/library/papers/26759240PubMed
939476340Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.N Engl J Med2024https://conductscience.org/library/papers/39476340PubMed
1031474751A new era of long-read sequencing for cancer genomics.J Hum Genet2020https://conductscience.org/library/papers/31474751PubMed
1116847462The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.Nat Rev Genet2006https://conductscience.org/library/papers/16847462PubMed
1216168105Somatic mutation and gain of copy number of PIK3CA in human breast cancer.Breast Cancer Res2005https://conductscience.org/library/papers/16168105PubMed
1324587488Classes of phosphoinositide 3-kinases at a glance.J Cell Sci2014https://conductscience.org/library/papers/24587488PubMed
1431928690Efficacy of PI3K inhibitors in advanced breast cancer.Ann Oncol2019https://conductscience.org/library/papers/31928690PubMed
1525533673PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Nat Rev Cancer2015https://conductscience.org/library/papers/25533673PubMed
1620569503Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.Breast Cancer Res2010https://conductscience.org/library/papers/20569503PubMed
1725284480Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.Cancer Cell2014https://conductscience.org/library/papers/25284480PubMed
1831091374Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med2019https://conductscience.org/library/papers/31091374PubMed
1932175074mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges.Cell Biosci2020https://conductscience.org/library/papers/32175074PubMed
2016724053Ras, PI(3)K and mTOR signalling controls tumour cell growth.Nature2006https://conductscience.org/library/papers/16724053PubMed

See all 58 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42668644A marine-derived meroterpenoid inhibits colorectal cancer via PI3K pathway modulation in mice.Mar Life Sci Technol2026https://conductscience.org/library/papers/42668644PubMed
42477186Identification of miR-21-5p and miR-21-3p regulated hub genes and drug repurposing targets in cervical cancer: an integrative computational analysis.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42477186PubMed
42296160Unlocking precision diagnostics: A multimodal framework integrating metabolomics with advanced machine learning techniques.PLoS One2026https://conductscience.org/library/papers/42296160PubMed
42113367Long non-coding RNAs as modulators of endocrine therapy response in hormone receptor-positive breast cancer.Mol Biol Rep2026https://conductscience.org/library/papers/42113367PubMed
42041716
Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.
Curr Oncol2026https://conductscience.org/library/papers/42041716PubMed
41976378Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.Cancers (Basel)2026https://conductscience.org/library/papers/41976378PubMed
41764610Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Mini Rev Med Chem2026https://conductscience.org/library/papers/41764610PubMed
41514656Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers (Basel)2025https://conductscience.org/library/papers/41514656PubMed
41512289Postpartum breast cancer: evidence for a distinct phenotype.J Natl Cancer Inst2026https://conductscience.org/library/papers/41512289PubMed
41233438Proteomics characterization of triple-negative apocrine carcinoma reveals molecular features of progression and chemotherapy response.Sci Rep2025https://conductscience.org/library/papers/41233438PubMed
41182651SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).Clin Transl Oncol2026https://conductscience.org/library/papers/41182651PubMed
41157256Breast Cancer Treatments: Drugs Targeting the PI3K/AKT/mTOR Pathway, TNBC Therapy and Future Directions: A Review.Life (Basel)2025https://conductscience.org/library/papers/41157256PubMed
40924238Targeting the tumor microenvironment in colorectal cancer: the effect of Rapamycin on angiogenesis, apoptosis, and STAT5A/TORC1 signaling.Mol Biol Rep2025https://conductscience.org/library/papers/40924238PubMed
40868155Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines2025https://conductscience.org/library/papers/40868155PubMed
40725184The Inositol-5-Phosphatase SHIP1: Expression, Regulation and Role in Acute Lymphoblastic Leukemia.Int J Mol Sci2025https://conductscience.org/library/papers/40725184PubMed
40676293PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40676293PubMed
40421216CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment.Front Pharmacol2025https://conductscience.org/library/papers/40421216PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39796647

GET https://conductscience.org/api/papers/v1/39796647/references?page=2